The proven software platform for cell and gene therapy supply chain management
Master medicine’s most complex supply chain
From science to product to patients and all points in between, Vineti has solved key challenges in providing personalized therapeutics. Vineti has your advanced therapy supply chain and data management covered.
Simplify workflows to focus more on patients and less on logistics.
Streamline and optimize the production process for cell therapies, gene therapies, and personalized cancer vaccines.
Achieve end-to-end supply chain visibility, control, and analytics for autologous and allogeneic therapeutics.
Maintain automated, industry-leading Chain of Identity, Chain of Custody, reporting, and data collection.
Manage operational complexity and data collection to keep your clinical trial program on track.
Navigate and win the “3D chess game” of personalized therapy commercialization.
Personalized Therapy Management®
PTM Enterprise™ – the complete end-to-end enterprise-grade software solution to industrialize and scale advanced therapies, ensuring standards, patient safety, data security, regulatory compliance, and a seamless customer experience
PTM Essentials™ – the purpose-built solution that accelerates advanced therapy clinical trials, helping studies start up quickly and run simply and scaling alongside your trial
Whether you have one system to connect or many, Vineti integrates critical systems to bring the workflow together — EBR, ERP, MES, IWRS, CRM, 3PL, SSO and more …
Orchestrating our ecosystem
Kite Pharma and Vineti enter strategic partnership to develop best-in-class logistics and data analytics software for engineered T-cell therapies at commercial scale
Vineti partners with World Courier to provide a state-of-the-art supply chain solution for global cell and gene therapy ecosystem
Deloitte and Vineti will team up on an end-to-end solution to support personalized medicine
Vineti and Quick Specialized Healthcare Logistics partner to share industry expertise that helps strengthen cell and gene therapy supply chains
Vineti™ to partner with Tessa Therapeutics™ to advance and scale cancer immunotherapies world-wide
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS (announcement includes work with Vineti)
Lonza partners with Vineti across its cell and gene therapy manufacturing network to optimize ‘vein-to-vein’ delivery service
Vineti and Cryoport Collaborate to Bring Integrated Solutions to the Global Regenerative Therapy Market
Vineti and WuXi AppTec Advanced Therapies Collaborate to Simplify Manufacturing Supply Chain for Advanced Therapies
Vineti Completes $35 Million in Series C Financing to Industrialize Personalized and High-Value Therapeutics
Together, Cardinal Health and Vineti offer integrated, innovative solutions for advanced therapies, helping pharma companies realize faster speed to market, reduced risk, and a more consistent customer experience.
Mavens’ Cell & Gene Navigator, built on Salesforce Health Cloud, supports cutting-edge concierge services that power patient services hubs for specialty pharma and rare disease, and will seamlessly integrate with Vineti’s personalized therapy management solution.
Integrated Commercial Services and Personalized Therapy Management system to seamlessly track product and patient journey
Avobis Bio and Vineti announce strategic collaboration to support new implantable cell therapies addressing debilitating conditions
Integrated Custom-Curated IO Clinical Trial Services and Personalized Therapy Management systems to seamlessly manage advanced therapy clinical journeys for cancer patients
Vineti and Marker Therapeutics announce strategic partnership to support diverse cell therapy portfolio
Vineti and OriBiotech announce a partnership to produce a fully pre-integrated solution to modernize, fast-track, and streamline the manufacture and delivery of cell and gene therapies.
Vineti and PRA Health Sciences announce a strategic relationship to support the operational challenges associated with autologous, allogeneic, and personalized therapeutics in cell and gene therapy (CGT) clinical trials.